However, the drug had opposing effects on AKT phosphorylation in the OSU‐CLL and OSU‐CLLTP53ko lines; in contrast to the primary samples and WT OSU‐CLL line, increased levels of AKT phosphorylation were observed in the TP53ko line following ONC‐212 treatment (Figure S2B). This evidence concerns the gene AKT1 and B-cell chronic lymphocytic leukemia.